
==== Front
J Clin Invest
J Clin Invest
J Clin Invest
The Journal of Clinical Investigation
0021-9738
1558-8238
American Society for Clinical Investigation

182652
10.1172/JCI182652
Viewpoint
The cancer-associated secretory phenotype: a new frontier in targeted therapeutics
https://orcid.org/0000-0002-8603-5700
Tan Xiaochao xiaochtan@163.com
1
https://orcid.org/0000-0003-3454-6717
Xiao Guan-Yu Guan-Yu.Xiao@uky.edu
2
https://orcid.org/0000-0001-9398-9345
Banerjee Priyam PBanerjee@mdanderson.org
3
Wang Shike SWang17@mdanderson.org
4
Kurie Jonathan M. jkurie@mdanderson.org
4
1 Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.
2 Department of Toxicology and Cancer Biology, University of Kentucky College of Medicine, Markey Cancer Center, Lexington, Kentucky, USA.
3 Bio-Imaging Resource Center, The Rockefeller University, New York, New York, USA.
4 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Address correspondence to: Jonathan M. Kurie, Department of Thoracic/Head and Neck Medical Oncology, Box 432, MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030, USA. Phone: 713.745.1504; Email: jkurie@mdanderson.org. Or to: Xiaochao Tan, Department of Medicine, Section of Hematology and Oncology, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA. Phone: 504.988.1244; Email: xtan4@tulane.edu.
3 9 2024
3 9 2024
3 9 2024
134 17 e182652© 2024 Tan et al.
2024
Tan et al.
https://creativecommons.org/licenses/by/4.0/ This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
This article is available online at https://www.jci.org/articles/view/182652
==== Body
pmcFollowing the acquisition of oncogenic mutations, cells undergo senescence and acquire heightened secretory states termed senescence-associated secretory phenotypes (SASPs). Proteins identified in SASPs include a broad range of inflammatory and immune-modulatory cytokines and chemokines, growth factors, and cell surface molecules. In seminal work from the laboratory of Judith Campisi, genotoxic stress was shown to induce senescence partly via SASPs (1). Oncogene expression also induces senescence, and proteins secreted in response to genotoxic stress or oncogenic RAS expression demonstrate a high degree of overlap (1). In work from the laboratory of Dafna Bar-Sagi, mutant RAS activates secretion in established cancer cells that gain tumorigenic activity following ectopic mutant RAS expression (2). Therefore, mutant RAS activates secretion in both senescent and nonsenescent cells. More recently, we identified other oncogenic signals that activate secretory programs in cancer cells, including p53 loss, chromosome 1q and 3q amplicons, and epithelial-mesenchymal transition (3–6). For the purposes of this discussion, oncogene-activated secretory programs in nonsenescent cancer cells will collectively be referred to herein as cancer-associated secretory phenotypes (CASPs).

Distinguishing CASP from SASP

SASPs and CASPs mediate their extracellular actions through partially overlapping sets of secreted effectors (1), but their upstream regulators appear to be distinct. Genotoxic stress activates SASPs through the transcription factor NF-κB, which drives the expression of interleukin-6 and -8, indicating that heightened expression of secreted effectors sustains SASPs. Not surprisingly, SASPs are also regulated by classical protein secretory pathway components, including PKD1, ARF1, and PI4KIIIβ (7). In contrast, somatic mutations activate CASPs by initiating cargo-specific secretory vesicle biogenesis in the Golgi and accelerating anterograde trafficking of secretory vesicles from Golgi to plasma membrane (3, 4, 8). Embedded within the CASP regulatory network are Golgi-resident protein complexes that govern cargo sorting, Golgi membrane bending, and vesicle scission (3, 4, 8, 9). Cargo-sorting proteins recognize and load specific cargos into secretory vesicles (10). In line with these observations, CASPs govern the secretion of specific cargos (3–5).

Secretory blockade as a therapeutic strategy

Based on evidence from preclinical models (11), antibodies and decoy receptors designed to neutralize individual secreted effectors in the extracellular space were tested in patients with cancer (11). These approaches demonstrated limited efficacy (11). While multiple factors could have contributed to these disappointing outcomes, functional redundancy within the cancer secretome may have negated any antitumor activity of the neutralization approaches. Therefore, strategies to block the entire cancer secretome, rather than the actions of single peptides in the extracellular space, warrant consideration. In line with evidence that the cancer secretome contains a broad range of effectors that maintain cancer cell survival and drive immunosuppression and fibrosis in the tumor microenvironment (3, 12), secretory blockade induces apoptosis in tumor cells, restores antitumor immunity, and reverses acquired resistance to immune checkpoint inhibitor therapies in preclinical models (12). Consequently, strategies have been developed based on an understanding of how oncogenic mutations interface with the conventional secretory pathway (Figure 1).

Secretory vesicle biogenesis in the Golgi requires phosphatidylinositol-4-phosphate (PI4P), the Golgi membrane insertion site for Golgi phosphoprotein 3 (GOLPH3), and other proteins that drive vesicle extraction from Golgi membranes (9). Golgi-resident PI4P is generated by two enzymes, PI4KIIIβ and PI4KIIα (13). High levels of these enzymes initiate secretory vesicle biogenesis (3, 5, 14). Selective antagonists of PI4KIIIβ or PI4KIIα induce secretory blockade and tumor regression (3, 5). Sensitivity to these agents is tightly linked to a PI4KIIIβ-encoding chromosome 1q amplicon and a PI4KIIα-upregulating transcriptional program activated by epithelial-mesenchymal transition (Figure 1A) (3, 5).

Golgi-resident scaffolds coordinate client proteins dedicated to a common task (15). The scaffolds Golgi integral membrane protein 4 (GOLIM4) and Golgi reassembly and stacking protein 55 kDa (GRASP55) recruit protein complexes that coordinate cargo loading, Golgi membrane curvature, and vesicle scission to activate CASPs (6, 8). Pharmacologic strategies to degrade GOLIM4 or inhibit GRASP55/client interactions induce secretory blockade and tumor regression (6, 8). Sensitivity to these agents is tightly linked to a GOLIM4-encoding chromosome 3q amplicon (Figure 1B) and a GRASP55-upregulating transcriptional program activated by p53 loss (Figure 1C) (6, 8).

p53 loss leads to high expression of the Golgi scaffold PAQR11 and enhances the secretion of protease urokinase plasminogen activator (PLAU), which activates autocrine signals that accelerate secretory vesicle biogenesis in the Golgi, completing a prosecretory feed-forward loop in p53-deficient cancer cells (4). Pharmacologic or genetic approaches to interrupt the PLAU-dependent autocrine loop block secretion and inhibit tumor growth and metastasis (4). PLAU secretion and sensitivity to PLAU antagonists are tightly linked to p53 deficiency (Figure 1D) (4).

Candidate secretory antagonists

PI4K antagonists that are under development as antiviral agents inhibit secretion and exert selective antitumor activity against chromosome 1q–amplified malignancies (3). Originally developed as a male contraceptive (16), a small molecule that inhibits GRASP55/client protein interactions inhibits secretion and exerts antitumor activity in p53-deficient tumor models (8). Systemic manganese (Mn) delivery to mice bearing chromosome 3q–amplified malignancies degrades intratumoral GOLIM4, inhibits secretion, and induces tumor regression (6). In a phase I study, intranasal Mn delivery was well tolerated in patients with advanced cancer (17). Given that chromosome 1q and 3q amplicons are largely mutually exclusive from known actionable oncogenic mutations (3, 6), novel agents are needed for chromosome 1q– and 3q–amplified malignancies. It’s important to note that both cancer and healthy cells utilize the same Golgi secretory pathway, suggesting that blocking it could affect noncancerous cells as well. However, cancer cells demonstrate an increased reliance on factors from heightened secretion, driven by the amplification or upregulation of Golgi genes (4–6, 8, 18) or somatic driver mutations (4, 8). This heightened dependency makes cancer cells more sensitive to inhibition of secretion compared with healthy cells, presenting a potential therapeutic window.

Summary

Oncogenic mutations activate secretory programs that drive tumor progression and represent therapeutic targets. The clinical relevance of CASPs is underscored by their prevalence, their linkages to specific genetic and epigenetic contexts, the proven efficacy of secretory blockade in preclinical models, and the availability of assays to identify vulnerable patient populations.

This work was supported in part by grants from the NIH (R01CA236781 and R01CA255021-01 to JMK and 5R03CA280382-03 to XT). JMK holds the Gloria Lupton Tennison Distinguished Professorship in Lung Cancer.

Version 1 09/03/2024

Electronic publication

Figure 1 Blockade of secretory vesicle biogenesis provides a therapeutic strategy for targeting cancer.

(A) Phosphatidylinositol-4-phosphate (PI4P) is the Golgi membrane insertion site for Golgi phosphoprotein 3 (GOLPH3), a pivotal regulator of Golgi membrane dynamics and vesicle biogenesis. Golgi PI4P is generated by two Golgi-localized phosphatidylinositol 4-kinases (PI4Ks): PI4KIIIβ and PI4KIIα. PI4K antagonists block PI4P synthesis and impair secretion. (B) Golgi scaffold GOLIM4 recruits effectors of vesicle biogenesis (GOLPH3) and cargo sorting (ATP2C1) to activate secretion. GOLIM4 is degraded by manganese (Mn), resulting in diminished secretion. (C) P53 loss increased the expression levels of the Golgi scaffold GRASP55. GOLGIN45 is a client of GRASP55 and generates a protein complex that promotes vesicle biogenesis. GRASPIN disrupts the interaction between GRASP55 and GOLGIN45. (D) The Golgi scaffold PAQR11 is induced upon the loss of P53. PAQR11 promotes the secretion of PLAU, which functions in an autocrine manner by binding to the PLAU receptor (PLAUR). Activated PLAUR, in turn, promotes the expression of PAQR11. PLAUR inhibitor (PLAURi) prevents the binding of secreted PLAU to PLAUR, effectively terminating an autocrine signaling pathway that drives secretion.

Conflict of interest: JMK is a paid consultant for Terasom Ltd. PB is a paid consultant for ExpertConnect LLC and has spousal income and equity from Eli Lilly and Company. JMK and XT have a pending patent application: “Compositions and methods of treatment for lung cancer” (US 63/483,705).

Copyright: © 2024, Tan et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: J Clin Invest. 2024;134(17):e182652. https://doi.org/10.1172/JCI182652.
==== Refs
1 Coppe JP et al Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor PLoS Biol 2008 6 12 2853 2868 10.1371/journal.pbio.0060301 19053174
2 Pylayeva-Gupta Y et al Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia Cancer Cell 2012 21 6 836 847 10.1016/j.ccr.2012.04.024 22698407
3 Tan X et al PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma Sci Transl Med 2020 12 527 eaax3772 10.1126/scitranslmed.aax3772 31969487
4 Tan X et al p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi Sci Adv 2021 7 25 eabf4885 10.1126/sciadv.abf4885 34144984
5 Tan X et al EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer J Clin Invest 2023 133 7 e165863 10.1172/JCI165863 36757799
6 Tan X et al Chromosomal 3q amplicon encodes essential regulators of secretory vesicles that drive secretory addiction in cancer J Clin Invest 2024 134 12 e176355 10.1172/JCI176355 38662435
7 Su Y et al The protein kinase D1-mediated classical protein secretory pathway regulates the Ras oncogene-induced senescence response J Cell Sci 2018 131 6 jcs207217 10.1242/jcs.207217 29420297
8 Tan X et al A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma J Clin Invest 2021 131 1 e137186 10.1172/JCI137186 32931483
9 Dippold HC et al GOLPH3 bridges phosphatidylinositol-4-phosphate and actomyosin to stretch and shape the Golgi to promote budding Cell 2009 139 2 337 351 10.1016/j.cell.2009.07.052 19837035
10 Crevenna AH et al Secretory cargo sorting by Ca2+-dependent Cab45 oligomerization at the trans-Golgi network J Cell Biol 2016 213 3 305 314 10.1083/jcb.201601089 27138253
11 Coussens LM et al Matrix metalloproteinase inhibitors and cancer: trials and tribulations Science 2002 295 5564 2387 2392 10.1126/science.1067100 11923519
12 Xiao GY et al EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer Proc Natl Acad Sci U S A 2023 120 28 e2220276120 10.1073/pnas.2220276120 37406091
13 Graham TR Burd CG Coordination of Golgi functions by phosphatidylinositol 4-kinases Trends Cell Biol 2011 21 2 113 121 10.1016/j.tcb.2010.10.002 21282087
14 Shi L et al Addiction to Golgi-resident PI4P synthesis in chromosome 1q21.3-amplified lung adenocarcinoma cells Proc Natl Acad Sci U S A 2021 118 25 e2023537118 10.1073/pnas.2023537118 34155143
15 Kulkarni-Gosavi P et al Form and function of the Golgi apparatus: scaffolds, cytoskeleton and signalling FEBS Lett 2019 593 17 2289 2305 10.1002/1873-3468.13567 31378930
16 Cartier-Michaud A et al Genetic, structural, and chemical insights into the dual function of GRASP55 in germ cell Golgi remodeling and JAM-C polarized localization during spermatogenesis PLoS Genet 2017 13 6 e1006803 10.1371/journal.pgen.1006803 28617811
17 Lv M et al Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy Cell Res 2020 30 11 966 979 10.1038/s41422-020-00395-4 32839553
18 Tan X et al Epithelial-to-mesenchymal transition drives a pro-metastatic Golgi compaction process through scaffolding protein PAQR11 J Clin Invest 2017 127 1 117 131 10.1172/JCI88736 27869652
